EWTX
EWTX clinical trials: Edgewise Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Edgewise Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 19
- Trials linked
- 17
- As lead sponsor
- 2
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
EWTX on the catalyst calendar · EWTX registry changes
- Primary completion Dec 2027Sponsor estimatePhase 2NCT07795814A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)Edgewise Therapeutics, Inc. · Heart Failure With Preserved Ejection FractionRecruitingEWTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 7, 2026ActualPhase 2NCT05291091Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)Edgewise Therapeutics, Inc. · Becker Muscular DystrophyCompletedEWTXLeadMEDPCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2031Sponsor estimatePhase 2NCT06066580Open-Label Extension of EDG-5506 in Participants With Becker Muscular DystrophyEdgewise Therapeutics, Inc. · Becker Muscular DystrophyEnrolling by invitationEWTXLeadMEDPCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 29, 2026ActualPhase 1NCT07177066A Study of EDG-15400 in Healthy AdultsEdgewise Therapeutics, Inc. · Healthy AdultsCompletedEWTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 1, 2026ActualPhase 1NCT07456059A Study to Evaluate EDG-7500 in Caucasian and Japanese AdultsEdgewise Therapeutics, Inc. · Healthy Adult ParticipantsCompletedEWTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 7, 2026ActualPhase 1NCT07324616A Study to Evaluate EDG-7500 in Adults With Hepatic ImpairmentEdgewise Therapeutics, Inc. · Hepatic Impairment (HI)CompletedEWTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 2NCT06347159A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)Edgewise Therapeutics, Inc. · Hypertrophic CardiomyopathyActive, not recruitingEWTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 22, 2025ActualPhase 1NCT07034768A Study to Evaluate EDG-7500 in People With Renal ImpairmentEdgewise Therapeutics, Inc. · Renal ImpairmentsCompletedEWTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimatePhase 2NCT05540860A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)Edgewise Therapeutics, Inc. · Duchenne Muscular DystrophyActive, not recruitingEWTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2027Sponsor estimatePhase 2NCT06100887Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene TherapyEdgewise Therapeutics, Inc. · Duchenne Muscular DystrophyActive, not recruitingEWTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 1, 2024ActualPhase 1NCT05160415A Study of EDG-5506 in Adult Males With Becker Muscular DystrophyEdgewise Therapeutics, Inc. · Becker Muscular DystrophyCompletedEWTXLeadMEDPCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 17, 2025ActualPhase 1NCT06738836A Study to Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C]-EDG-7500Edgewise Therapeutics, Inc. · Healthy VolunteerCompletedEWTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 22, 2025ActualPhase 1NCT06916897A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy VolunteersEdgewise Therapeutics, Inc. · Healthy SubjectsCompletedEWTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 23, 2024ActualPhase 1NCT06011317A Study of EDG-7500 in Healthy AdultsEdgewise Therapeutics, Inc. · Healthy SubjectsCompletedEWTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 6, 2023ActualPhase 1NCT05730842Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy VolunteersEdgewise Therapeutics, Inc. · Healthy VolunteerCompletedEWTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 19, 2022ActualPhase 1NCT05492734A Study to Assess the Feasibility of Non-invasive Dried Blood SamplingEdgewise Therapeutics, Inc. · Muscular DystrophiesCompletedEWTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 15, 2021ActualPhase 1NCT04585464A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy AdultsEdgewise Therapeutics, Inc. · Healthy VolunteerCompletedEWTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2026ActualNo phase registeredNCT05257473Defining Endpoints in Becker Muscular DystrophyVirginia Commonwealth University · Becker Muscular DystrophyCompletedEWTXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 20, 2021ActualNo phase registeredNCT04349566Fast Troponin as a Biomarker to Assess Exercise-induced Muscle Damage in Muscle DiseasesMads Peter Godtfeldt Stemmerik · Becker Muscular DystrophyCompletedEWTXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 19 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner